Abstract
Runt-related gene 3 (RUNX3) inactivation by promoter hypermethylation correlates with poor clinical outcome and occurs in 70% of lung adenocarcinomas. Nicotinamide, a well-known sirtuin inhibitor, re-activates the epigenetically silenced tumor suppressor RUNX3 in cancer cells. We examined whether the addition of nicotinamide to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) increases the survival of stage IV lung cancer patients with EGFR mutations (exon 19 or 21 mutation).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
